RESULTS OF A PHASE I STUDY OF GMI-1271, A NOVEL E-SELECTIN ANTAGONIST IN COMBINATION WITH INDUCTION CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE
EHA Library, Helen Thackray,
133179
SAFETY STUDY OF CRENOLANIB, A TYPE I FLT3 INHIBITOR, WITH CYTARABINE/DAUNORUBICIN OR CYTARABINE/IDARUBICIN INDUCTION AND HIGH-DOSE CYTARABINE CONSOLIDATION IN NEWLY DIAGNOSED FLT3+ AML
EHA Library, Eunice Wang,
133174
ORAL THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG TREATMENT DURING INDUCTION CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY
EHA Library, Noëlle Frey,
133173